Remdesivir effect in the treatment of corona
Not Applicable
Completed
- Conditions
- Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
- Registration Number
- CTRI/2020/10/028657
- Lead Sponsor
- Department of pharmacology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 1193
Inclusion Criteria
Covid rapid test positive or Rt-PCR test positive
SpO2 level less than 94% or Xray suggestive of pneumonia.
Exclusion Criteria
Patients file with incomplete details
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Remdesivir's antiviral activity against SARS-CoV-2 in CTRI/2020/10/028657?
How does Remdesivir compare to standard-of-care treatments for moderate-to-severe COVID-19 in observational studies?
Which biomarkers correlate with clinical outcomes in Remdesivir-treated patients from CTRI/2020/10/028657?
What adverse events are associated with Remdesivir therapy in CTRI/2020/10/028657 and how were they managed?
How do Remdesivir's RNA-dependent RNA polymerase inhibition effects compare to other nucleotide analogs like Favipiravir in SARS-CoV-2 treatment?